Patent Linkage. ArriVent will be solely responsible for making all decisions required or allowed in the United States, in the FDA’s Orange Book, the FDA’s Purple Book, in the European Union, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 and in any other country in the Licensed Territory under the equivalent Regulatory Agencies in such country that are applicable to Allist Patent Rights or Joint Patent Rights licensed hereunder; provided, that, ArriVent will reasonably consult with Allist with respect to such decisions and implement the reasonable comments and concerns of Allist and Allist shall reasonably cooperate with ArriVent in connection with such actions.
Patent Linkage. To the extent required by Applicable Law, Hutchmed shall use Commercially Reasonable Efforts to promptly, accurately and completely list, with the applicable Regulatory Authorities in the Territory, all applicable Patents for any Licensed Product that Hutchmed intends to, or has begun to, Commercialize and that have become the subject of an application for Regulatory Approval submitted to Regulatory Authorities in the Territory. Prior to such listings, the Parties shall meet to evaluate and identify all applicable Patents, and Hutchmed shall retain final decision-making authority as to the listing of all applicable Patents for such Licensed Product in the Territory, regardless of which Party owns such Patent.
Patent Linkage. As between the Parties, [***] shall have the [***] right, at its sole cost and expense, to obtain patent term extensions, supplementary protection certificates, and equivalents thereof with respect to any [***] Licensed Patent in any country in the Territory, provided that [***] shall [***].
Patent Linkage. 45 12. CONFIDENTIALITY................................................................................................................... 45 12.1
Patent Linkage. Merck (or its designee) may list or submit any C4T Patent Right or Joint Residual Patent Right with any Regulatory Authority in the Territory in connection with the Development, Regulatory Approval or Commercialization of a Collaboration Product to the extent required under Applicable Law, and C4T shall reasonably assist Merck in connection therewith at Merck’s cost; provided that, Merck shall notify C4T in advance and discuss in good faith any patent linkage of any C4T Platform Patent Right or C4T Collaboration Patent Right, to
Patent Linkage. The Parties are urged to implement alternatively, one of the two Patent Linkage systems recognized in this new legislation. These systems are:
Patent Linkage. [***] (or its designee) shall have the sole right, but not the obligation, to list, with the applicable Regulatory Authorities in the Territory, all applicable Patents (including any Immatics Patents or Joint Patents) for any BMS Product, including all so called “Purple Book” listings required under the U.S. Public Health Service Act, and all similar listings in any other relevant countries, and [***] shall have no right to do so. For the avoidance of doubt, [***].
Patent Linkage. MSD (or its designee) may list or submit any Evaxion Patent Right licensed to MSD under this Agreement or Joint Patent Right with any Regulatory Authority in the Territory in connection with the development, regulatory approval or commercialization of a Product, and Evaxion shall reasonably assist MSD in connection therewith at MSD’s cost.
